Eikon Therapeutics filed to raise roughly $317 million in a Nasdaq IPO to accelerate its oncology protein‑dynamics platform and associated drug discovery pipeline. The company, founded by former industry executives, is positioning its high‑resolution platform as a tool to discover small molecules and biologics informed by spatiotemporal protein behaviors. Proceeds will fund R&D, platform expansion and potential early‑stage clinical programs. The IPO attempt underscores renewed public markets appetite for platform biotech that pair proprietary instrumentation and AI‑driven discovery. Investors will scrutinize Eikon’s translational roadmap, lead indications and capital efficiency as the company moves from platform validation into therapeutic development.